Bio-Techne Corporation, a global life sciences company, announced it has reached an agreement to acquire Asuragen Inc, a biotechnology company for initial consideration of US$ 215 million in cash plus contingent
BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it is supplying the peripheral blood mononuclear cells (PBMCs) for Promega Corporation’s new PBMC Antibody-Dependent Cellular Cytotoxicity (ADCC) Bioassay. This bioassay uses PBMCs to mimic in vivo conditions and measure the ADCC of antibodies during drug development and characterization.
“This new platform combines BioIVT’s high quality, physiologically representative PBMCs with Promega’s reliable, quantitative readout technology to deliver more consistent results than traditional primary cell ADCC bioassays,” said BioIVT chief commercial officer Alan Findlater.
The PBMC ADCC Bioassay is the first kit to offer ADCC-qualified PBMCs alongside Promega technologies. It incorporates a simple add-mix-read format and sensitive luminescent readout, yielding a robust assay window. There are a variety of assay formats, providing ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. Upon target-cell killing, a bright luminescent signal is generated.
“BioIVT was uniquely positioned to support this assay development. Promega staff pre-screened and evaluated many of our recallable donors to identify those that were most reactive in their assay. Consequently, Promega was able to enhance its kit and ensure that its customers receive optimal responses for their immuno-oncology research. We look forward to continuing to partner with Promega to develop additional bioassays using human primary cells,” Findlater added.
BioIVT operates seven donor centers, under FDA or HTA approval as appropriate, allowing it to supply fresh biospecimens to customers throughout the US, UK, and Europe. The company processes more than 40,000 donations annually from diverse donor cohorts and has access to more than 400 recallable donors, providing a rich inventory of PBMCs. All its biospecimens receive viral screening to guarantee product safety and are delivered with detailed socio-demographic and clinical data.
BioIVT’s donor centers all work under strict institutional review board approved protocols to ensure patient safety and high product quality. They are also strategically located so that they can provide same-day fresh materials to global biotechnology hubs.
With extensive immune cell isolation expertise, BioIVT provides customers with purified PBMCs, immune cell subsets, and CD34+ hematopoietic stem cells to meet their research needs. It also provides high-definition human leukocyte antigen typing for immune cell products. In addition, BioIVT can produce custom orders to fast-track customers’ research and development programmes.
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. The company specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids.
